| Autor: |
Dean HF; Cancer Research UK Centre, Cancer Sciences Division, University of Southampton, Faculty of Medicine, Southampton, UK., Cazaly A, Hurlock C, Borras J, Williams AP, Johnson PW, Davies AJ |
| Jazyk: |
angličtina |
| Zdroj: |
Bone marrow transplantation [Bone Marrow Transplant] 2012 Dec; Vol. 47 (12), pp. 1545-51. Date of Electronic Publication: 2012 May 14. |
| DOI: |
10.1038/bmt.2012.73 |
| Abstrakt: |
The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ≥3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P = < 0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P < 0.001). Naive CD8(+) lymphocytes (P = 0.014) and transitional B cells (P = 0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/auto-SCT followed by appropriate revaccination. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
